BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 27261178)

  • 1. Novel JAK1-selective benzimidazole inhibitors with enhanced membrane permeability.
    Kim H; Kim MK; Choo H; Chong Y
    Bioorg Med Chem Lett; 2016 Jul; 26(14):3213-3215. PubMed ID: 27261178
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Benzimidazole Derivatives as Potent JAK1-Selective Inhibitors.
    Kim MK; Shin H; Park KS; Kim H; Park J; Kim K; Nam J; Choo H; Chong Y
    J Med Chem; 2015 Sep; 58(18):7596-602. PubMed ID: 26351728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-based design and development of (benz)imidazole pyridones as JAK1-selective kinase inhibitors.
    Simov V; Deshmukh SV; Dinsmore CJ; Elwood F; Fernandez RB; Garcia Y; Gibeau C; Gunaydin H; Jung J; Katz JD; Kraybill B; Lapointe B; Patel SB; Siu T; Su H; Young JR
    Bioorg Med Chem Lett; 2016 Apr; 26(7):1803-8. PubMed ID: 26927423
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 4-Amino-pyrrolopyridine-5-carboxamide: a novel scaffold for JAK1-selective inhibitors.
    Shin H; Kim MK; Chong Y
    Chem Pharm Bull (Tokyo); 2014; 62(3):217-20. PubMed ID: 24583775
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of selective inhibitors for the treatment of rheumatoid arthritis: (R)-3-(3-(Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)-3-oxopropanenitrile as a JAK1-selective inhibitor.
    Chough C; Joung M; Lee S; Lee J; Kim JH; Kim BM
    Bioorg Med Chem; 2018 May; 26(8):1495-1510. PubMed ID: 29452839
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of azabenzimidazoles as potent JAK1 selective inhibitors.
    Vasbinder MM; Alimzhanov M; Augustin M; Bebernitz G; Bell K; Chuaqui C; Deegan T; Ferguson AD; Goodwin K; Huszar D; Kawatkar A; Kawatkar S; Read J; Shi J; Steinbacher S; Steuber H; Su Q; Toader D; Wang H; Woessner R; Wu A; Ye M; Zinda M
    Bioorg Med Chem Lett; 2016 Jan; 26(1):60-7. PubMed ID: 26614408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective JAK1 inhibitor and selective Tyk2 inhibitor patents.
    Norman P
    Expert Opin Ther Pat; 2012 Oct; 22(10):1233-49. PubMed ID: 22971156
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The discovery of 2,5-isomers of triazole-pyrrolopyrimidine as selective Janus kinase 2 (JAK2) inhibitors versus JAK1 and JAK3.
    Lee SM; Yoon KB; Lee HJ; Kim J; Chung YK; Cho WJ; Mukai C; Choi S; Kang KW; Han SY; Ko H; Kim YC
    Bioorg Med Chem; 2016 Nov; 24(21):5036-5046. PubMed ID: 27555284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diamino-1,2,4-triazole derivatives are selective inhibitors of TYK2 and JAK1 over JAK2 and JAK3.
    Malerich JP; Lam JS; Hart B; Fine RM; Klebansky B; Tanga MJ; D'Andrea A
    Bioorg Med Chem Lett; 2010 Dec; 20(24):7454-7. PubMed ID: 21106455
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Linear propargylic alcohol functionality attached to the indazole-7-carboxamide as a JAK1-specific linear probe group.
    Kim MK; Shin H; Cho SY; Chong Y
    Bioorg Med Chem; 2014 Feb; 22(3):1156-62. PubMed ID: 24398382
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of triazolo [1,5-a] pyridine derivatives as novel JAK1/2 inhibitors.
    Lu K; Wu W; Zhang C; Liu Z; Xiao B; Yuan Z; Li A; Chen D; Zhai X; Jiang Y
    Bioorg Med Chem Lett; 2020 Jul; 30(14):127225. PubMed ID: 32527540
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design and optimization of a series of 4-(3-azabicyclo[3.1.0]hexan-3-yl)pyrimidin-2-amines: Dual inhibitors of TYK2 and JAK1.
    Fensome A; Ambler CM; Arnold E; Banker ME; Clark JD; Dowty ME; Efremov IV; Flick A; Gerstenberger BS; Gifford RS; Gopalsamy A; Hegen M; Jussif J; Limburg DC; Lin TH; Pierce BS; Sharma R; Trujillo JI; Vajdos FF; Vincent F; Wan ZK; Xing L; Yang X; Yang X
    Bioorg Med Chem; 2020 May; 28(10):115481. PubMed ID: 32253095
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anilino-monoindolylmaleimides as potent and selective JAK3 inhibitors.
    McDonnell ME; Bian H; Wrobel J; Smith GR; Liang S; Ma H; Reitz AB
    Bioorg Med Chem Lett; 2014 Feb; 24(4):1116-21. PubMed ID: 24461299
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conformational restriction of a type II FMS inhibitor leading to discovery of 5-methyl-
    Im D; Moon H; Kim J; Oh Y; Jang M; Hah JM
    J Enzyme Inhib Med Chem; 2019 Dec; 34(1):1716-1721. PubMed ID: 31571509
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of potent and efficacious pyrrolopyridazines as dual JAK1/3 inhibitors.
    Hynes J; Wu H; Kempson J; Duan JJ; Lu Z; Jiang B; Stachura S; Tokarski JS; Sack JS; Khan JA; Lippy JS; Zhang RF; Pitt S; Shen G; Gillooly K; McIntyre K; Carter PH; Barrish JC; Nadler SG; Salter-Cid LM; Fura A; Schieven GL; Pitts WJ; Wrobleski ST
    Bioorg Med Chem Lett; 2017 Jul; 27(14):3101-3106. PubMed ID: 28539220
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 9H-Carbazole-1-carboxamides as potent and selective JAK2 inhibitors.
    Zimmermann K; Sang X; Mastalerz HA; Johnson WL; Zhang G; Liu Q; Batt D; Lombardo LJ; Vyas D; Trainor GL; Tokarski JS; Lorenzi MV; You D; Gottardis MM; Lippy J; Khan J; Sack JS; Purandare AV
    Bioorg Med Chem Lett; 2015 Jul; 25(14):2809-12. PubMed ID: 25987372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of pyrrolo[1,2-b]pyridazine-3-carboxamides as Janus kinase (JAK) inhibitors.
    Duan JJ; Lu Z; Jiang B; Yang BV; Doweyko LM; Nirschl DS; Haque LE; Lin S; Brown G; Hynes J; Tokarski JS; Sack JS; Khan J; Lippy JS; Zhang RF; Pitt S; Shen G; Pitts WJ; Carter PH; Barrish JC; Nadler SG; Salter-Cid LM; McKinnon M; Fura A; Schieven GL; Wrobleski ST
    Bioorg Med Chem Lett; 2014 Dec; 24(24):5721-5726. PubMed ID: 25453808
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of WO-2013040863, WO-2013041042 and WO-2013043962. Selective JAK1 inhibitors based on a 3-aminopyrazole-4-carboxamide scaffold.
    Norman P
    Expert Opin Ther Pat; 2014 Feb; 24(2):231-7. PubMed ID: 24261748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery and Biological Evaluation of
    Park E; Lee SJ; Moon H; Park J; Jeon H; Hwang JS; Hwang H; Hong KB; Han SH; Choi S; Kang S
    J Med Chem; 2021 Jan; 64(2):958-979. PubMed ID: 33428419
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure activity optimization of 6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyrazines as Jak1 kinase inhibitors.
    Friedman M; Frank KE; Aguirre A; Argiriadi MA; Davis H; Edmunds JJ; George DM; George JS; Goedken E; Fiamengo B; Hyland D; Li B; Murtaza A; Morytko M; Somal G; Stewart K; Tarcsa E; Van Epps S; Voss J; Wang L; Woller K; Wishart N
    Bioorg Med Chem Lett; 2015 Oct; 25(20):4399-404. PubMed ID: 26372653
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.